

Didier ROGNAN

*Laboratoire d'Innovation Thérapeutique
UMR 7200 Université de Strasbourg/CNRS
F-67400 ILLKIRCH
49 years old*



Diplomas

- 1998: Habilitation (ETH Zürich, Switzerland)
"Molecular modelling of protein-peptide interactions: Application to Major Histocompatibility Complex proteins and design of nonpeptide ligands."
- 1989: Ph.D in Medicinal Chemistry, University Louis Pasteur, Strasbourg.
Thesis: "Computer-aided design and synthesis of D-2 dopaminergic antagonists."
Supervisor: Prof. WERMUTH, Centre de Neurochimie du CNRS, Strasbourg, France.
- 1985: Diplôme d' Etudes Approfondies (D.E.A) in Medicinal Chemistry, University Louis Pasteur, Strasbourg.
Topic: "Computer-aided design and synthesis of D-2 dopaminergic antagonists."
- 1984: Pharm.D , Rennes University
Thesis: "Synthesis of 11- β substituted.19-nor steroids"

Professional situations

- 2011-: CNRS Research Director (1st class)
- 2000-2010: CNRS Research Director (2nd class)
- 2006-2010: Cheminformatics project manager, IDEALP Pharma (Villeurbanne, France)
- 1996-2000: Assistant Professor, ETH Zürich (Departement of Applied Biosciences, Prof. G. Folkers)
- 1992-1995: Assistant, ETH Zürich (Departement of Pharmacy, Prof. G. Folkers)
- 1991: Post-doctoral fellowship, Laboratoires Fournier, Dijon, France
- 1989-1990: Post-doctoral fellowship, University of Tübingen, Germany (Dr. FOLKERS).
"Molecular dynamics simulation of MHC-peptide complexes"

Expertise

Medicinal chemistry, molecular modelling, virtual screening

Scientific production and evaluation

ca. 115 publications, 5 patents, h-index (29)

Last AERES evaluation: A+ (Excellent)

Member of the recently approved Laboratoire d' Excellence (Labex): Centre de Recherche du Médicament MEDALIS

Awards

2001 CGC American Chemical Society Award, 1995 PHOENIX Award, 1984 RECOPHAR Award

Miscellaneous

- Member of the Evaluation Committee of the French National Research Agency (ANR)

- Member of the editorial board of several journals
- Member of the Administration board of the Société Française de Chémoinformatique
- Member of the scientific board of IDEALP Pharma
- Scientific adviser of The Danish Council for Independent Research
- Consultant in rational drug design for various pharmaceutical companies (AstraZeneca, SanofiAventis, Servier, Solvay Pharmaceuticals)